The developing trend of monoclonal antibodies in the treatment of colorectal cancer

Expert Opinion on Biological Therapy

Volumn 7, Issue 6, 2007, Pages 871-883

  Elfiky, Aymen A ^a   Saif, Muhammad W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Avastin; Bevacizumab; Cetuximab; Colorectal cancer; EGFR; EMD 72000; Epidermal growth factor receptor; Erbitux; Matuzumab; Monoclonal antibodies; Panitumumab; Targeted biologic therapy; Vascular endothelial growth factor; Vectibix; VEGF; VEGF r; VEGF trap

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EDRECOLOMAB; EMD 273066; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KS IL 2; MAB 17 1A; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMC 1C11; OXALIPLATIN; PANITUMUMAB; RECOMBINANT INTERLEUKIN 2; TUCOTUZUMAB CELMOLEUKIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ACNE; ANAPHYLAXIS; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; EPISTAXIS; FEVER; HEADACHE; HUMAN; HYPERTENSION; METASTASIS; MONOTHERAPY; PROTEINURIA; RASH; REVIEW; THROMBOEMBOLISM; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250762589     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.6.871     Document Type: Review

References (70)

1. HARRIS M: Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. (2004) 5:292-302.
2. CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118-129.
3. ARTEAGA CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. (2001) 19:32S-40S.
4. SALOMON DS, BRANDT R, CIARDIELLO F et al.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19:183-232.
5. CARPENTER G: Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev. Biochem. (1987) 56:881-914.
6. CARPENTER G, COHEN S: Epidermal growth factor. J. Biol. Chem. (1990) 265:7709-7712.
7. KIM ES, KHURI FR, HERBST RS: Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol. (2001) 13:506-513.
8. WELLS A: EGF receptor. Int. J. Biochem. Cell Biol. (1999) 31:637-643.
9. YASUI W, SUMIYOSHI H, HATA J et al.: Expression of epidermal growth factor receoptor in human gastric and colonic carcinomas. Cancer Res. (1988) 48:137-141.
10. GOLDSTEIN NI, PREWETT M, ZUKLYS K et al.: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
11. HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 59:1935-1940.
12. WU X, FAN Z, MASUI H et al.: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. (1995) 95:1897-1907.
13. WU X, RUBIN M, FAN Z et al.: Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 12:1397-1403.
14. LIU B, FANG M, SCHMIDT M et al.: Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer (2000) 82:1991-1999.
15. HUANG SM, HARARI PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6:2166-2174.
16. NARAMURA M, GILLIES SD, MENDELSOHN J et al.: Therapeutic potential of chimeric and murine anti-epidermal growth factor receptor antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. (1993) 37:343-349.
17. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345. •• Pivotal study that led to the FDA approval of cetuximab in combination with irinotecan for the treatment of EGFR-positive, irinotecan-refractory mCRC and of cetuximab monotherapy in patients with EGFR-positive, irinotecan-refractory mCRC who were deemed to be intolerant of irinotecan.
18. SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001):Abstract 7.
19. SALTZ LB, MEROPOL NJ, LOEHRER PJ Sr. et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:1201-1028.
20. SALTZ LB, LENZ H, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3508. • Important trial which revealed that the addition of bevacizumab enhanced the efficacy of cetuximab monotherapy and the combination of cetuximab and irinotecan therapy.
21. DIAZ RUBIO E, TABERNERO J, VAN CUTSEM E et al.: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international Phase II study. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3535.
22. ROUGIER P, RAOUL J-L, VAN LAETHEM J-L et al.: Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3513.
23. VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX)±cetuximab for patients with untreated metastatic adenocarcinoma of the colon of rectum (MCRC): CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 3509.
24. ABUBAKR Y, ENG C, PAUTRET V et al.: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of 800 patients in a randomized Phase III trial (EPIC). Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 3556.
25. BADARINATH S, MITCHELL EP, JENNIS A et al.: Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary safety analysis of a randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3531.
26. JENNIS A, POLIKOFF J, MITCHELL E et al.: Erbitux (Cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized Phase III trial. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3574.
27. ARTEAGA CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist (2002) 4(Suppl. 7):31-39.
28. NICHOLSON RI, GEE JM, HARPER ME: EGFR and cancer prognosis. Eur. J. Cancer (2001) 4(Suppl. 37):S9-S15.
29. LENZ HJ, MAYER RJ, GOLD PJ et al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3510.
30. CHUNG KY, SHIA J, KEMENY NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. (2005) 23:1803-1810. • Retrospective study which suggests that EGFR positivity has little predictive value in terms of cetuximab activity.
31. MALIK I, HECHT JR, PATNAIK A et al.: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Proc. Am. Soc. Clin. Oncol. (2005):Abstract 3520.
32. MEROPOL NJ, BERLIN J, HECHT JR et al.: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2003):Abstract 1026.
33. PEETERS M, VAN CUTSEM E, SIENA S et al.: A Phase III, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer (mCRC), 97th AACR Annual Meeting, 2006. •• Pivotal Phase III trial that shows that panitumumab significantly increased progression-free survival (PFS) compared with best supportive care alone.
34. BERLIN J, MALIK I, PICUS J et al.: Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients with metastatic colorectal cancer. Ann. Oncol. (2004) 15(Suppl. 3):iii70:Abstract 265PD.
35. BERLIN J, POSEY J, TCHEKMEDYIAN S et al.: First line therapy of panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment of metastatic colorectal cancer. Eur. J. Cancer Suppl. (2005) 3:185:Abstract 653.
36. TRARBACH T, BEYER T, SCHLEUCHER N et al.: Randomized Phase I pharmacodynamic study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with advanced EGFR-expressing tumors: preliminary results of an ongoing study. Clin. Cancer Res. (2003) 9:6069S:Abstract A112.
37. TABERNERO J, ROJO F, JIMENEZ E et al.: A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-(q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with advanced tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:192:Abstract 770.
38. VANHOEFER U, TEWES M, ROJO F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:175-184.
39. VAN CUTSEM E, HUMBLET Y, GELDERBLOM H et al.: Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. Proceedings of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, Fla. 2007:Abstract 237.
40. FERRARA N, GERBER HP: The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. (2001) 106:148-156.
41. FERRARA N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. (2002) 29:10-14.
42. FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669-676.
43. KIM KJ, LI B, HOUCK K et al.: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors (1992) 7:53-64.
44. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593-4599.
45. KABBINAVAR F, HURWITZ H, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
46. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342. •• Pivotal randomized Phase III study showing that patients who received BV plus standard bolus weekly IFL regimen had longer progression-free survival and overall survival than those receiving IFL chemotherapy alone plus placebo.
47. KABBINAVIR FF, SCHULZ J, McCLEOD M et al.: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. (2005) 23:3697-3705.
48. SALTZ LB, CLARKE S, DIAZ-RUBIO E et al.: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized Phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Results from the 2007 Gastrointestinal Cancers Symposium.
49. GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO (2005):Abstract 2. •• The first Phase III study to demonstrate the ability of bevacizumab to enhance the efficacy of an oxaliplatin-based regimen.
50. HOCHSTER HS, WELLES L, HART L, et al.: Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized 'TREE-2' trial. GI ASCO (2005):Abstract 241. • Represents the first clinical study to document the clinical efficacy and safety profile of bevacizumab in combination with oxaliplatin-based regimens in the first-line setting.
51. HEDRICK E, KOZLOFF M, HAINSWORTH J et al.: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). Proceedings of the American Society of Clinical Oncology. (2006):Abstract 3536.
52. VAN CUTSEM E, MICHAEL M, BERRY S et al.: Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for mCRC: first BEA Trial. GI ASCO (2006):Abstract 250.
53. HURWITZ HI, FEHRENBACHER L, HAINSWORTH JD et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. (2005) 23:3502-3508.
54. BETSHOLTZ C, ARMULIK A: Homeostatic functions of vascular endothelial growth factor in adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. (2006) 290: H509-H511.
55. WULFF C, WILSON H, WIEGAND SJ et al.: Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology (2002) 143:2797-2807.
56. KONNER J, DUPONT J: Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin. Colorectal Cancer (2004) 4(Suppl. 2):S81-S85.
57. LAU SC, ROSA DD, JAYSON G: Technology evaluation: VEGF Trap (cancer), Regeneron/Sanofi-Aventis. Curr. Opin. Mol. Ther. (2005) 7:493-501.
58. WONG AK, ALFERT M, CASTRILLON DH et al.: Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc. Natl Acad. Sri. USA (2001) 98:7481-7486.
59. DUPONT J, SCHWARTZ L, KOUTCHER J et al.: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously to patients with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3009.
60. DUPONT J, CAMASTRA D, GORDON MS et al.: Phase I study of VEGF Trap in patients with solid tumors and lymphoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 776.
61. RIXE O, VERSLYPE C, MERIC JB et al.: Safety and pharmacokinetics of intravenous VEGF Trap plus irinotecan, 5-fluorouracil, and leucovorin in a combination Phase I clinical trial of patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 13161.
62. POSEY JA, NG TC, YANG B et al.: A Phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. (2003) 9:1323-1332.
63. TRARBACH T, THOMAS AL, BARTEL C et al.: Preliminary Phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer. Eur. J. Cancer (2003) 1(Suppl. 5):S91:Abstract 297.
64. STEWARD WP, THOMAS A, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:259:Abstract 3556.
65. HECHT JR, TRARBACH E, JAEGER E et al.: A randomized, double-blind, placebo controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluoruoracil/leucovorin and PTK787/Zk222584 or placebo (CONFIRM-1). J. Clin. Oncol. (2005) 23(16s):1090s:Abstract LBA3.
66. Planned interim analysis of CONFIRM 2 trial of PTK/ZK indicates low probability of demonstrating overall survival benefit in second-line therapy for metastatic colorectal cancer [Press Release]. Novartis, July 28, 2005.
67. GOODWIN RA, TUTTLE SE, BUCCI DM: Tumor-associated antigen expression of primary and metastatic colorectal carcinomas detected by monoclonal antibody 17-1A. Am. J. Clin. Pathol. (1987) 88:462-477.
68. BALZAR M, WINTER J, DE BOER CJ, LITVINOV NV: The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. (1999) 17:699-712.
69. GOLDBERG RM: Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Onkologie (2005) 28:311-312.
70. www.clinicaltrials.gov